Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Extracellular Vesicles as Biological Shuttles for Targeted Therapies.

Raimondo S, Giavaresi G, Lorico A, Alessandro R.

Int J Mol Sci. 2019 Apr 15;20(8). pii: E1848. doi: 10.3390/ijms20081848. Review.

2.

Anti-human CD9 antibody Fab fragment impairs the internalization of extracellular vesicles and the nuclear transfer of their cargo proteins.

Santos MF, Rappa G, Karbanová J, Vanier C, Morimoto C, Corbeil D, Lorico A.

J Cell Mol Med. 2019 Jun;23(6):4408-4421. doi: 10.1111/jcmm.14334. Epub 2019 Apr 13.

3.

Extracellular Vesicles from Thyroid Carcinoma: The New Frontier of Liquid Biopsy.

Rappa G, Puglisi C, Santos MF, Forte S, Memeo L, Lorico A.

Int J Mol Sci. 2019 Mar 5;20(5). pii: E1114. doi: 10.3390/ijms20051114. Review.

4.

Clinical Significance of Extracellular Vesicles in Plasma from Glioblastoma Patients.

Osti D, Del Bene M, Rappa G, Santos M, Matafora V, Richichi C, Faletti S, Beznoussenko GV, Mironov A, Bachi A, Fornasari L, Bongetta D, Gaetani P, DiMeco F, Lorico A, Pelicci G.

Clin Cancer Res. 2019 Jan 1;25(1):266-276. doi: 10.1158/1078-0432.CCR-18-1941. Epub 2018 Oct 4.

5.

VAMP-associated protein-A and oxysterol-binding protein-related protein 3 promote the entry of late endosomes into the nucleoplasmic reticulum.

Santos MF, Rappa G, Karbanová J, Kurth T, Corbeil D, Lorico A.

J Biol Chem. 2018 Sep 7;293(36):13834-13848. doi: 10.1074/jbc.RA118.003725. Epub 2018 Jul 17.

6.

Prominin-1/CD133: Lipid Raft Association, Detergent Resistance, and Immunodetection.

Karbanová J, Lorico A, Bornhäuser M, Corbeil D, Fargeas CA.

Stem Cells Transl Med. 2018 Feb;7(2):155-160. doi: 10.1002/sctm.17-0223. Epub 2017 Dec 22.

7.

Observation-driven inquiry: Raman spectroscopic imaging illuminates cancer lipid metabolism.

Lorico A, Rappa G, Corbeil D, Le TT.

Stem Cell Investig. 2017 May 26;4:42. doi: 10.21037/sci.2017.04.09. eCollection 2017. No abstract available.

8.

The HDAC6 Inhibitor Tubacin Induces Release of CD133+ Extracellular Vesicles From Cancer Cells.

Chao OS, Chang TC, Di Bella MA, Alessandro R, Anzanello F, Rappa G, Goodman OB, Lorico A.

J Cell Biochem. 2017 Dec;118(12):4414-4424. doi: 10.1002/jcb.26095. Epub 2017 May 31.

PMID:
28452069
9.

Nuclear transport of cancer extracellular vesicle-derived biomaterials through nuclear envelope invagination-associated late endosomes.

Rappa G, Santos MF, Green TM, Karbanová J, Hassler J, Bai Y, Barsky SH, Corbeil D, Lorico A.

Oncotarget. 2017 Feb 28;8(9):14443-14461. doi: 10.18632/oncotarget.14804.

10.

Transmission of Information in Neoplasia by Extracellular Vesicles.

Lorico A, Corbeil D, Pawelek JM, Alessandro R.

Biomed Res Int. 2015;2015:289567. doi: 10.1155/2015/289567. Epub 2015 Nov 30. No abstract available.

11.
12.

Breast Cancer-Derived Extracellular Vesicles: Characterization and Contribution to the Metastatic Phenotype.

Green TM, Alpaugh ML, Barsky SH, Rappa G, Lorico A.

Biomed Res Int. 2015;2015:634865. doi: 10.1155/2015/634865. Epub 2015 Oct 27. Review.

13.

Extracellular vesicle-mediated transfer of CLIC1 protein is a novel mechanism for the regulation of glioblastoma growth.

Setti M, Osti D, Richichi C, Ortensi B, Del Bene M, Fornasari L, Beznoussenko G, Mironov A, Rappa G, Cuomo A, Faretta M, Bonaldi T, Lorico A, Pelicci G.

Oncotarget. 2015 Oct 13;6(31):31413-27. doi: 10.18632/oncotarget.5105.

14.

Tetraspanin CD9 determines invasiveness and tumorigenicity of human breast cancer cells.

Rappa G, Green TM, Karbanová J, Corbeil D, Lorico A.

Oncotarget. 2015 Apr 10;6(10):7970-91.

15.

Letter to the editor: An intriguing relationship between lipid droplets, cholesterol-binding protein CD133 and Wnt/β-catenin signaling pathway in carcinogenesis.

Rappa G, Fargeas CA, Le TT, Corbeil D, Lorico A.

Stem Cells. 2015 Apr;33(4):1366-70. doi: 10.1002/stem.1953. No abstract available.

16.

Adhesion signaling promotes protease‑driven polyploidization of glioblastoma cells.

Mercapide J, Lorico A.

Int J Mol Med. 2014 Nov;34(5):1365-71. doi: 10.3892/ijmm.2014.1913. Epub 2014 Aug 25.

PMID:
25174945
17.

The nuclear pool of tetraspanin CD9 contributes to mitotic processes in human breast carcinoma.

Rappa G, Green TM, Lorico A.

Mol Cancer Res. 2014 Dec;12(12):1840-50. doi: 10.1158/1541-7786.MCR-14-0242. Epub 2014 Aug 7.

18.

Biochemical and biological characterization of exosomes containing prominin-1/CD133.

Rappa G, Mercapide J, Anzanello F, Pope RM, Lorico A.

Mol Cancer. 2013 Jun 14;12:62. doi: 10.1186/1476-4598-12-62.

19.

Wnt interaction and extracellular release of prominin-1/CD133 in human malignant melanoma cells.

Rappa G, Mercapide J, Anzanello F, Le TT, Johlfs MG, Fiscus RR, Wilsch-Bräuninger M, Corbeil D, Lorico A.

Exp Cell Res. 2013 Apr 1;319(6):810-9. doi: 10.1016/j.yexcr.2013.01.003. Epub 2013 Jan 12.

20.

Relationship between tumor cell invasiveness and polyploidization.

Mercapide J, Anzanello F, Rappa G, Lorico A.

PLoS One. 2012;7(12):e53364. doi: 10.1371/journal.pone.0053364. Epub 2012 Dec 31.

21.

Prominin-1 (CD133) and Metastatic Melanoma: Current Knowledge and Therapeutic Perspectives.

Lorico A, Mercapide J, Rappa G.

Adv Exp Med Biol. 2013;777:197-211. doi: 10.1007/978-1-4614-5894-4_13.

PMID:
23161084
22.

Spontaneous formation of tumorigenic hybrids between breast cancer and multipotent stromal cells is a source of tumor heterogeneity.

Rappa G, Mercapide J, Lorico A.

Am J Pathol. 2012 Jun;180(6):2504-15. doi: 10.1016/j.ajpath.2012.02.020. Epub 2012 Apr 27.

23.

The intrinsic fusogenicity of glioma cells as a factor of transformation and progression in the tumor microenvironment.

Mercapide J, Rappa G, Lorico A.

Int J Cancer. 2012 Jul 15;131(2):334-43. doi: 10.1002/ijc.26361. Epub 2011 Aug 30.

24.

Cancer stem cells.

Lu B, Chiou SH, Deutsch E, Lorico A.

J Oncol. 2011;2011:269437. doi: 10.1155/2011/269437. Epub 2011 Apr 10. No abstract available.

25.

Phenotypic heterogeneity of breast cancer stem cells.

Lorico A, Rappa G.

J Oncol. 2011;2011:135039. doi: 10.1155/2011/135039. Epub 2011 Jan 17.

26.

Imatinib mesylate enhances the malignant behavior of human breast carcinoma cells.

Rappa G, Anzanello F, Lorico A.

Cancer Chemother Pharmacol. 2011 Apr;67(4):919-26. doi: 10.1007/s00280-010-1394-x. Epub 2010 Jul 2.

27.

Phenotypic characterization of mammosphere-forming cells from the human MA-11 breast carcinoma cell line.

Rappa G, Lorico A.

Exp Cell Res. 2010 May 15;316(9):1576-86. doi: 10.1016/j.yexcr.2010.01.012. Epub 2010 Jan 11.

28.

Primary gene-engineered neural stem/progenitor cells demonstrate tumor-selective migration and antitumor effects in glioma.

Mercapide J, Rappa G, Anzanello F, King J, Fodstad O, Lorico A.

Int J Cancer. 2010 Mar 1;126(5):1206-15. doi: 10.1002/ijc.24809.

29.

The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma.

Rappa G, Fodstad O, Lorico A.

Stem Cells. 2008 Dec;26(12):3008-17. doi: 10.1634/stemcells.2008-0601. Epub 2008 Sep 18.

30.

Growth of cancer cell lines under stem cell-like conditions has the potential to unveil therapeutic targets.

Rappa G, Mercapide J, Anzanello F, Prasmickaite L, Xi Y, Ju J, Fodstad O, Lorico A.

Exp Cell Res. 2008 Jun 10;314(10):2110-22. doi: 10.1016/j.yexcr.2008.03.008. Epub 2008 Mar 20.

31.

Primary neural stem/progenitor cells expressing endostatin or cytochrome P450 for gene therapy of glioblastoma.

Lorico A, Mercapide J, Solodushko V, Alexeyev M, Fodstad O, Rappa G.

Cancer Gene Ther. 2008 Sep;15(9):605-15. doi: 10.1038/cgt.2008.23. Epub 2008 Apr 18. Erratum in: Cancer Gene Ther. 2009 Jun;16(6):539. Soloduschko, V [corrected to Solodushko, V].

PMID:
18421309
32.

Gamma-glutamylcysteine synthetase-based selection strategy for gene therapy of chronic granulomatous disease and graft-vs.-host disease.

Rappa G, Anzanello F, Alexeyev M, Fodstad O, Lorico A.

Eur J Haematol. 2007 May;78(5):440-8. Epub 2007 Feb 27.

PMID:
17331133
33.

Resident education regarding technical aspects of cesarean section.

Dandolu V, Raj J, Harmanli O, Lorico A, Chatwani AJ.

J Reprod Med. 2006 Jan;51(1):49-54.

PMID:
16482777
34.

Outcome of uterine embolization and hysterectomy for leiomyomas.

Dandolu V, Lorico A.

Am J Obstet Gynecol. 2005 Jul;193(1):304-5; author reply 305-6. No abstract available.

PMID:
16021096
35.

Gamma-glutamylcysteine synthetase and L-buthionine-(S,R)-sulfoximine: a new selection strategy for gene-transduced neural and hematopoietic stem/progenitor cells.

Lorico A, Bratbak D, Meyer J, Kunke D, Krauss S, Plott WE, Solodushko V, Baum C, Fodstad O, Rappa G.

Hum Gene Ther. 2005 Jun;16(6):711-24.

PMID:
15960602
36.

Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients.

Koyanagi K, Kuo C, Nakagawa T, Mori T, Ueno H, Lorico AR Jr, Wang HJ, Hseuh E, O'Day SJ, Hoon DS.

Clin Chem. 2005 Jun;51(6):981-8. Epub 2005 Apr 7.

37.

Efficient expansion and gene transduction of mouse neural stem/progenitor cells on recombinant fibronectin.

Rappa G, Kunke D, Holter J, Diep DB, Meyer J, Baum C, Fodstad O, Krauss S, Lorico A.

Neuroscience. 2004;124(4):823-30.

PMID:
15026123
38.

Apparent lack of Mrp1-mediated efflux at the luminal side of mouse blood-brain barrier endothelial cells.

Cisternino S, Rousselle C, Lorico A, Rappa G, Scherrmann JM.

Pharm Res. 2003 Jun;20(6):904-9.

PMID:
12817896
39.
40.

Role of the Multidrug Resistance Protein 1 in protection from heavy metal oxyanions: investigations in vitro and in MRP1-deficient mice.

Lorico A, Bertola A, Baum C, Fodstad O, Rappa G.

Biochem Biophys Res Commun. 2002 Mar 1;291(3):617-22.

PMID:
11855834
41.

Role of the multidrug resistance protein 1 gene in the carcinogenicity of aflatoxin B1: investigations using mrp1-null mice.

Lorico A, Nesland J, Emilsen E, Fodstad O, Rappa G.

Toxicology. 2002 Feb 28;171(2-3):201-5.

PMID:
11836025
43.

Erythrocyte membrane ATP binding cassette (ABC) proteins: MRP1 and CFTR as well as CD39 (ecto-apyrase) involved in RBC ATP transport and elevated blood plasma ATP of cystic fibrosis.

Abraham EH, Sterling KM, Kim RJ, Salikhova AY, Huffman HB, Crockett MA, Johnston N, Parker HW, Boyle WE Jr, Hartov A, Demidenko E, Efird J, Kahn J, Grubman SA, Jefferson DM, Robson SC, Thakar JH, Lorico A, Rappa G, Sartorelli AC, Okunieff P.

Blood Cells Mol Dis. 2001 Jan-Feb;27(1):165-80.

PMID:
11358378
44.

Structure-activity studies of novobiocin analogs as modulators of the cytotoxicity of etoposide (VP-16).

Rappa G, Shyam K, Lorico A, Fodstad O, Sartorelli AC.

Oncol Res. 2000;12(3):113-9.

PMID:
11216669
45.

Phase I and pharmacokinetic study of novobiocin in combination with VP-16 in patients with refractory malignancies.

Murren JR, DiStasio SA, Lorico A, McKeon A, Zuhowski EG, Egorin MJ, Sartorelli AC, Rappa G.

Cancer J. 2000 Jul-Aug;6(4):256-65.

PMID:
11038146
46.

Novobiocin-induced VP-16 accumulation and MRP expression in human leukemia and ovarian carcinoma cells.

Rappa G, Murren JR, Johnson LM, Lorico A, Sartorelli AC.

Anticancer Drug Des. 2000 Apr;15(2):127-34.

PMID:
10901300
47.

New insights into the biology and pharmacology of the multidrug resistance protein (MRP) from gene knockout models.

Rappa G, Finch RA, Sartorelli AC, Lorico A.

Biochem Pharmacol. 1999 Aug 15;58(4):557-62. Review.

PMID:
10413292
48.

Altered efflux properties of mouse leukemia L1210 cells resistant to 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.

Cory JG, Cory AH, Lorico A, Rappa G, Sartorelli AC.

Anticancer Res. 1997 Sep-Oct;17(5A):3185-93.

PMID:
9413147
49.
50.

Supplemental Content

Loading ...
Support Center